Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 11
Submit an article Journal homepage
197
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Ixazomib and dexamethasone in high risk smoldering multiple myeloma: a clinical and correlative pilot study

Sham Mailankodya Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA;b Department of Medicine, Weill Cornell Medical College, New York, NY, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2815-9561View further author information
ORCID Icon,
Meghan Salcedoa Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Elizabet Tavitianc PRA Health Sciences, Raleigh, NC, USAView further author information
,
Miranda Burgea Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Neha Kordea Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA;b Department of Medicine, Weill Cornell Medical College, New York, NY, USAORCID Iconhttps://orcid.org/0000-0002-5538-4318View further author information
ORCID Icon,
Hani Hassouna Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA;b Department of Medicine, Weill Cornell Medical College, New York, NY, USAORCID Iconhttps://orcid.org/0000-0002-2036-1749View further author information
ORCID Icon,
Alexander Lesokhina Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA;b Department of Medicine, Weill Cornell Medical College, New York, NY, USAORCID Iconhttps://orcid.org/0000-0001-9321-702XView further author information
ORCID Icon,
Oscar Lahoudb Department of Medicine, Weill Cornell Medical College, New York, NY, USA;d BMT service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USAORCID Iconhttps://orcid.org/0000-0002-3291-286XView further author information
ORCID Icon,
Eric Smithe Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USAView further author information
,
Malin Hultcrantza Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA;b Department of Medicine, Weill Cornell Medical College, New York, NY, USAView further author information
,
Carlyn Tana Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA;b Department of Medicine, Weill Cornell Medical College, New York, NY, USAORCID Iconhttps://orcid.org/0000-0001-7922-2594View further author information
ORCID Icon,
Urvi Shaha Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA;b Department of Medicine, Weill Cornell Medical College, New York, NY, USAORCID Iconhttps://orcid.org/0000-0001-8419-1091View further author information
ORCID Icon,
Sean Devlinf Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
&
Ola Landgrena Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA;g Myeloma Program and Experimental Therapeutics Program, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USAORCID Iconhttps://orcid.org/0000-0001-6485-4839View further author information
ORCID Icon show all
Pages 2760-2761 | Received 08 Apr 2022, Accepted 20 Jun 2022, Published online: 15 Jul 2022

References

  • Ahn IE, Mailankody S, Korde N, et al. Dilemmas in treating smoldering multiple myeloma. J Clin Oncol. 2015;33(1):115–123.
  • Landgren O. Shall we treat smoldering multiple myeloma in the near future? Hematology Am Soc Hematol Educ Program. 2017;2017(1):194–204.
  • Mateos MV, Hernandez MT, Giraldo P, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013;369(5):438–447.
  • Mateos MV, Hernandez MT, Giraldo P, et al. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Lancet Oncol. 2016;17(8):1127–1136.
  • Lonial S, Jacobus S, Fonseca R, et al. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J Clin Oncol. 2020;38(11):1126–1137.
  • Landgren CO, Chari A, Cohen YC, et al. Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). Leukemia. 2020;34(7):1840–1852.
  • Kumar S, Paiva B, Anderson KC, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e346.
  • Bustoros M, Nadeem O, Sperling AS, et al. Phase II trial of the combination of ixazomib, lenalidomide, and dexamethasone in High-Risk smoldering multiple myeloma. Blood. 2019;134(Supplement_1):580–580.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.